: 64 3 Vol. 64, No. 3, March, 2003

C S

, ¹
. 1. 1. 1. 1

Acute Arterial Occlusion Associated with Protein C and S Deficiencies

Eun Young Jung, M.D., Yong Pil Cho, M.D.¹, Hyuk Jai Jang, M.D.¹, Jee Soo Kim, M.D.¹, Yong Ho Kim, M.D.¹ and Myoung Sik Han, M.D.¹

Sudden acute arterial occlusion can result from a multitude of pathological processes. Although the appearance and the secondary effects of an acute arterial occlusion are similar regardless of the underlying cause, the treatment and prognosis are different. Therefore, establishing a correct diagnosis is crucial. Acute arterial occlusion is most frequently a complication of ischemic cardiac disease, with an atrial fibrillation occurring in most patients. An identifiable noncardiac source of the acute arterial occlusion can be found in 5~10% of patients. Howerver, in these cases, the specific source of the occlusion cannot be determined clinically or even at autopsy. Possible hypercoagulable states should be suspected and appropriately evaluated, particularly in patients with no history of antecedent occlusive disease who present with sudden arterial occlusions, or in patients with malignant disease. Protein C and protein S deficiencies are frequently described as a cause of the hypercoagulable states. We reported 3 cases of acute arterial occlusion associated with protein C and S deficiencies. (J Korean Surg Soc 2003;64:269-274)

Key Words: Acute disease, Arterial occlusion, Protein C,
Protein S, Deficiency
., , C , S

Department of Surgery, University of Ulsan College of Medicine, Seoul Asan Hospital, Seoul, ¹Department of Surgery, Gangneung Asan Hospital, Gangneung, Korea

: , 415 \$\text{\Pi}\$ 210-711, Tel: 033-610-3229, Fax: 033-641-8120 E-mail: ypcho@knh.co.kr : 2002 10 24 , : 2002 10 30 . 80~90% 7\frac{5~10\%}{5~10\%}
. (1-3)

. 1845 Virchow Virchow , 3가 가 3가 가 .(4) 3가 '(hypercoagulable state) . C S C S .(5-12)C S 3

1.
68 8
(pain), (pallor), (paresthesia),
(poikilothermia) .

가 것 외에 특이 소견은 없었다. 혈액 화학 검사 결과 간기능



Fig. 1. Femoral arteriographic findings in case 1. (A) Preoperative arteriography showed complete occlusion of left superficial femoral artery. (B) Intraoperative arteriography showed patent femoral and popliteal artery suggesting successful thrombectomy.

(acute limb ischemia clinical 가 category IIb).(13) (Fig. 1B) (patch angioplasty) 가 (Fig. 1A). (transesophageal echocardiography) heparin sodium 15% S . C Fogarty catheter

: C S 271



Fig. 2. Femoral arteriographic findings in case 2. (A) Preoperative arteriography showed left distal superficial femoral artery occlusion about 10-cm in length. (B) Intraoperative arteriography showed patent femoral and popliteal artery suggesting successful thrombectomy.

(acute limb ischemia clinical category III).(13)

10-cm

(Fig. 2A).

sodium .

Fogarty catheter .

. 가 2B)

· 가




Fig. 3. In case 3, preoperative arteriography showed complete occlusion of left common iliac artery.

S 59% 12% . C S

(reperfusion injury)
(Fig. . (demarcation)

3.71 8

```
272
```

: 64 3 2003

```
.(14)
                                                      (90/60
             (104/min)
                                                                      80~90% 가
mmHg),
                   가
                                                                              5~10%
2~3
                                                                              5~10%
        3
                               가
                                       가
                                                                     .(1-3)
                                        가
  (acute limb ischemia clinical category IIb).(13)
                                                                     1845
                                                                            Virchow
                                                                                                  , 3가
                                                                                            가
                                                                           Virchow
                          (Fig. 3). Heparin sodium
                                                                             3가
                                                                                                가
                                                                                                                         3가
                                                                                                         .(4)
                                          Fogarty catheter
                            가
                                                                                                                   . C
                                                                                                                            S
                                                                            C
                                                                                    S
                                                                                                                    .(5-12)
                                             7-cm
                                                                     C
                                                                            S
                                                                                                K
                     가
                                                                      C
                                                                                                 (activated protein C)
                                                                              factor Va VIIIa
                                                                  \mathsf{C}
                                                                               tissue plasminogen activator
       C
                                   29%
                                                                  (natural fibrinolytic activity)
                                                                                                             .(15,16) S
                                                                     C
                                                                                            (cofactor)
                                                                                                                      . C
(paraneoplastic syndrome)
                                                                  S
                                                가
                                                                  (homozygous form)
                                                                                                           \mathsf{C}
                                                                       (heterozygous form)
                                                                                                                        60%
                                                                                        C
                                                                                               S
                                                                  \mathsf{C}
                                                                            S
                                                                                4~5%
                                                                                          C
                                                                                                     S
                                                                                                      .(5-12,15-18) C
                                                                                                                            S
                         가,
                가,
                            가,
(prosthetic device)
                                                                              가
  가
                                                                                             \mathbf{C}
                                                                                                        S
```

273

Human protein C/S 'NL' NANORID TM radial immunodiffusion kit (The Binding Site Ltd, Birmingham, UK) . C S C S $60{\sim}140\%$. 3 C S . 3

. 2 C S 1 . C S 7 C S

가 .(16) . 가 가 C S 가 . C S 가 가 ,

C S

REFERENCES

- Elliott JP Jr, Hageman JH, Szilagyi E, Ramakrishnan V, Bravo JJ, Smith RF. Arterial embolization: problems of source, multi plicity, recurrence, and delayed treatment. Surgery 1980;88: 833-45.
- Abbott WM, Maloney RD, McCabe CC, Lee CE, Wirthlin LS. Arterial embolism: a 44 year perspective. Am J Surg 1982; 143:460-64.
- 3) Panetta T, Thompson JE, Talkington CM, Garrett WV, Smith BL. Arterial embolectomy: a 34-year experience with 400 cases. Surg Clin North Am 1986;66:339-53.
- Virchow R. Phlogose und thrombose. In: Virchow R, editor. Gesammelte Abband-lungen zur Wissenschaflichen Medizin. Frankfurt: Van Meidlinger Sohn; 1856. p.458-636.
- Cho YP, Lee DH, Jang HJ, Kim JS, Han MS, Lee SG. Peripheral arterial insufficiency associated with protein C deficiency. Br J Radiol 2002;75:843-6.
- 6) Cho YP, Lee DH, Jung SM, Jang HJ, Kim JS, Han MS. Vascular diseases associated with protein C and/or S de ficiencies. J Korean Surg Soc 2002;62:181-6.
- Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, et al. Inherited thrombophilia: Part 1. Thromb Haemost 1996;76:651-62.
- 8) Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, et al. Inherited thrombophilia: Part 2. Thromb Haemost 1996;76:824-34.
- De Stefano V, Finazzi G, Mannucci PM. Inherited throm bophilia: Pathogenesis, clinical syndromes, and management. Blood 1996;87:3531-44.
- 10) De Stefano V, Leone G, Mastrangelo S, Tripodi A, Rodeghiero F, Castaman G, et al. Clinical manifestations and management of inherited thrombophilia: Retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1994;72:352-58.
- 11) Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briet E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993;341:134-38.
- 12) Eldrup-Jorgensen J, Flanigan DP, Brace L, Sawchuk AP, Mulder SG, Anderson CP, et al. Hypercoagulable states and lower limb ischemia in young adults. J Vasc Surg 1989;9:

334-41.

- 13) Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. Recommended standards for reports dealing with lower extremity ischemia: Revised version. J Vasc Surg 1997;26:517-38.
- 14) Brewster DC. Acute peripheral arterial occlusion. Cardiol Clin 1991;9:497-513.
- 15) Clouse LH, Comp PC. The regulation of hemostasis: the protein C system. N Engl J Med 1986;314:1298-304.
- 16) Bick RL, Pegram M. Syndromes of hypercoagulability and thrombosis: a review. Semin Thromb Hemost 1994;20:109-32.
- 17) Sakata T, Kario K, Katayama Y, Matsuyama T, Kato H, Miyata T. Studies on congenital protein C deficiency in Japanese: prevalence, genetic analysis, and relevance to the onset of arterial occlusive diseases. Seminars Thromb Hemost 2000;26:11-6.
- 18) Sakata T, Kario K, Katayama Y, Matsuyama T, Kato H, Miyata T. Analysis of 45 episodes of arterial occlusive disease in Japanese patients with congenital protein C deficiency. Thromb Res 1999;94:69-78.
- 19) Esmon CT. The regulation of natural anticoagulant pathways. Science 1987;235:1348-52.